Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.

Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM.

Clin Cancer Res. 2018 Feb 15;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327. Epub 2017 Nov 30.

PMID:
29191972
2.

Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.

Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, Marien KM, Kockx MM, Husain A, Birrer MJ; NRG Oncology/Gynecologic Oncology Group.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx066.

PMID:
29059426
3.

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ.

Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27.

PMID:
28756902
4.

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.

Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.

Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049.

5.

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS.

Lancet Oncol. 2017 Jun;18(6):779-791. doi: 10.1016/S1470-2045(17)30279-6. Epub 2017 Apr 21.

6.

Weekly vs. Every-3-Week Paclitaxel for Ovarian Cancer.

Chan JK, Brady MF, Monk BJ.

N Engl J Med. 2016 Jun 30;374(26):2603-4. doi: 10.1056/NEJMc1603849. No abstract available.

7.

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ.

N Engl J Med. 2016 Feb 25;374(8):738-48. doi: 10.1056/NEJMoa1505067.

8.

Reply to F.M. Muggia.

Bookman MA, Brady MF.

J Clin Oncol. 2016 Mar 10;34(8):884. doi: 10.1200/JCO.2015.63.4303. Epub 2016 Feb 1. No abstract available.

PMID:
26834059
9.

Inherited Mutations in Women With Ovarian Carcinoma.

Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ.

JAMA Oncol. 2016 Apr;2(4):482-90. doi: 10.1001/jamaoncol.2015.5495.

10.

Intraperitoneal chemotherapy: long-term outcomes revive a long-running debate.

Bookman MA, Brady MF.

J Clin Oncol. 2015 May 1;33(13):1424-6. doi: 10.1200/JCO.2014.60.2797. Epub 2015 Mar 23. No abstract available.

PMID:
25800752
11.

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX.

J Clin Oncol. 2014 Apr 20;32(12):1210-7. doi: 10.1200/JCO.2013.53.6524. Epub 2014 Mar 17.

12.

Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Villella JA, Alvarez RD.

Gynecol Oncol. 2014 Jan;132(1):8-17. doi: 10.1016/j.ygyno.2013.11.008. Epub 2013 Nov 15.

13.

Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Burger RA, Brady MF, Rhee J, Sovak MA, Kong G, Nguyen HP, Bookman MA.

Gynecol Oncol. 2013 Oct;131(1):21-6. doi: 10.1016/j.ygyno.2013.07.100. Epub 2013 Jul 29.

14.

Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.

Stehman FB, Brady MF, Thigpen JT, Rossi EC, Burger RA.

Gynecol Oncol. 2012 Dec;127(3):495-501. doi: 10.1016/j.ygyno.2012.09.002. Epub 2012 Sep 19.

15.

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group.

N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.

16.

CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.

Gardner GJ, Baser RE, Brady MF, Bristow RE, Markman M, Spriggs D, Thaler HT.

Gynecol Oncol. 2012 Feb;124(2):216-20. doi: 10.1016/j.ygyno.2011.10.021. Epub 2011 Oct 25.

PMID:
22033034
17.

Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective.

Oza AM, Castonguay V, Tsoref D, Diaz-Padilla I, Karakasis K, Mackay H, Welch S, Weberpals J, Hoskins P, Plante M, Provencher D, Tonkin K, Covens A, Ghatage P, Gregoire J, Hirte H, Miller D, Rosen B, Maroun J, Buyse M, Coens C, Brady MF, Stuart GC.

Curr Oncol. 2011 Oct;18 Suppl 2:S20-7.

18.

A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.

Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H.

Gynecol Oncol. 2011 Jul;122(1):89-94. doi: 10.1016/j.ygyno.2011.03.013. Epub 2011 May 6.

19.

Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: a gynecologic oncology group study.

Farley J, Smith LM, Darcy KM, Brady MF, Bell J, McGuire W, Birrer MJ.

Gynecol Oncol. 2011 May 1;121(2):395-401. doi: 10.1016/j.ygyno.2010.11.023. Epub 2011 Feb 18.

PMID:
21310472
20.

Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.

Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH.

Gynecol Oncol. 2011 May 1;121(2):358-63. doi: 10.1016/j.ygyno.2010.12.354. Epub 2011 Jan 28.

21.

EORTC 55971: does it apply to all patients with advanced state ovarian cancer?

Rose PG, Brady MF.

Gynecol Oncol. 2011 Feb;120(2):300-1. doi: 10.1016/j.ygyno.2010.10.021. Epub 2010 Nov 20. No abstract available.

PMID:
21093893
22.

The MIT D-lab electricity-free PortaTherm™ incubator for remote testing with the QuantiFERON®-TB Gold In-Tube assay.

Dominguez M, Smith A, Luna G, Brady MF, Austin-Breneman J, Lopez S, Yataco R, Moore DA.

Int J Tuberc Lung Dis. 2010 Nov;14(11):1468-74.

23.

Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study.

Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA.

Cancer. 2011 Feb 1;117(3):554-62. doi: 10.1002/cncr.25460. Epub 2010 Sep 22.

24.
25.

Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.

Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A; Gynecologic Cancer InterGroup.

Int J Gynecol Cancer. 2010 Aug;20(6):945-52. doi: 10.1111/IGC.0b013e3181dd0110. Review.

PMID:
20683400
26.

Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons.

Reddy KP, Brady MF, Gilman RH, Coronel J, Navincopa M, Ticona E, Chavez G, Sánchez E, Rojas C, Solari L, Valencia J, Pinedo Y, Benites C, Friedland JS, Moore DA.

Clin Infect Dis. 2010 Apr 1;50(7):988-96. doi: 10.1086/651081.

27.

Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia.

Bern C, Verastegui M, Gilman RH, Lafuente C, Galdos-Cardenas G, Calderon M, Pacori J, Del Carmen Abastoflor M, Aparicio H, Brady MF, Ferrufino L, Angulo N, Marcus S, Sterling C, Maguire JH.

Clin Infect Dis. 2009 Dec 1;49(11):1667-74. doi: 10.1086/648070.

28.

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM.

J Clin Oncol. 2009 Mar 20;27(9):1419-25. doi: 10.1200/JCO.2008.19.1684. Epub 2009 Feb 17. Erratum in: J Clin Oncol. 2009 May 1;27(13):2305.

29.

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis.

Brady MF, Coronel J, Gilman RH, Moore DA.

J Vis Exp. 2008 Aug 11;(17). pii: 845. doi: 10.3791/845.

30.

Reducing the string test intra-gastric downtime for detection of Mycobacterium tuberculosis.

Bae WH, Salas A, Brady MF, Coronel J, Colombo CG, Castro B, Gilman RH, Moore DA.

Int J Tuberc Lung Dis. 2008 Dec;12(12):1436-40.

PMID:
19017454
31.

Tibiofemoral compression force differences using laxity- and force-based initial graft tensioning techniques in the anterior cruciate ligament-reconstructed cadaveric knee.

Fleming BC, Brady MF, Bradley MP, Banerjee R, Hulstyn MJ, Fadale PD.

Arthroscopy. 2008 Sep;24(9):1052-60. doi: 10.1016/j.arthro.2008.05.013. Epub 2008 Jun 30.

32.

Corticosteroids reduce postoperative morbidity after third molar surgery: a systematic review and meta-analysis.

Markiewicz MR, Brady MF, Ding EL, Dodson TB.

J Oral Maxillofac Surg. 2008 Sep;66(9):1881-94. doi: 10.1016/j.joms.2008.04.022. Review.

PMID:
18718396
33.

Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M.

J Clin Oncol. 2007 Oct 1;25(28):4466-71.

PMID:
17906207
34.
35.

Directly observed highly active antiretroviral therapy for HIV-infected children in Cambodia.

Myung P, Pugatch D, Brady MF, Many P, Harwell JI, Lurie M, Tucker J.

Am J Public Health. 2007 Jun;97(6):974-7. Epub 2007 Apr 26.

36.

Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study.

Huang HQ, Brady MF, Cella D, Fleming G.

Int J Gynecol Cancer. 2007 Mar-Apr;17(2):387-93.

PMID:
17362317
37.

Effects of initial graft tension on the tibiofemoral compressive forces and joint position after anterior cruciate ligament reconstruction.

Brady MF, Bradley MP, Fleming BC, Fadale PD, Hulstyn MJ, Banerjee R.

Am J Sports Med. 2007 Mar;35(3):395-403. Epub 2007 Jan 11.

38.

Frictional properties of Hartley guinea pig knees with and without proteolytic disruption of the articular surfaces.

Teeple E, Fleming BC, Mechrefe AP, Crisco JJ, Brady MF, Jay GD.

Osteoarthritis Cartilage. 2007 Mar;15(3):309-15. Epub 2006 Sep 28.

39.

Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time.

Armstrong DK, Brady MF.

J Clin Oncol. 2006 Oct 1;24(28):4531-3. No abstract available.

PMID:
17008690
40.

Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM; Gynecologic Oncology Group.

Gynecol Oncol. 2006 Sep;102(3):432-9. Epub 2006 Jul 24.

PMID:
16860852
41.

Clinical trials in ovarian carcinoma: study methodology.

Vermorken JB, Parmar MK, Brady MF, Eisenhauer EA, Hogberg T, Ozols RF, Rochon J, Rustin GJ, Sagae S, Verheijen RH; Gynecologic Cancer Intergroup; EORTC; MRC/NCRI; GOG; NCIC-CTG; NSGO; AGO-OVAR; JGOG.

Ann Oncol. 2005;16 Suppl 8:viii20-viii29. No abstract available.

PMID:
16239233
42.

Secondary surgical cytoreduction for advanced ovarian carcinoma.

Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH, Small JM; Gynecologic Oncology Group.

N Engl J Med. 2004 Dec 9;351(24):2489-97.

43.

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S.

J Clin Oncol. 2004 Oct 1;22(19):3902-8.

PMID:
15459211
44.

Analysis of CHEK2 gene for ovarian cancer susceptibility.

Baysal BE, DeLoia JA, Willett-Brozick JE, Goodman MT, Brady MF, Modugno F, Lynch HT, Conley YP, Watson P, Gallion HH.

Gynecol Oncol. 2004 Oct;95(1):62-9.

PMID:
15385111
45.

Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.

Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, Alberts DS.

J Clin Oncol. 2003 Dec 1;21(23):4350-5.

PMID:
14645424
46.

Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study.

Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, Wadler S, Spiegel G, Arbuck SG.

J Clin Oncol. 2003 Aug 1;21(15):2843-8. Epub 2003 Jun 13.

PMID:
12807937
47.

Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study.

Bloss JD, Brady MF, Liao SY, Rocereto T, Partridge EE, Clarke-Pearson DL; Gynecologic Oncology Group Study.

Gynecol Oncol. 2003 Apr;89(1):148-54.

PMID:
12694669
49.

Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study.

Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE.

Gynecol Oncol. 2001 Nov;83(2):355-62.

PMID:
11606097
50.

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP.

J Clin Oncol. 2001 Jun 15;19(12):2975-82.

PMID:
11408492

Supplemental Content

Loading ...
Support Center